From: SARS-CoV-2 host cell entry: an in silico investigation of potential inhibitory roles of terpenoids
a) Lipinski filter analysis | ||||
 Lipinski filters | T1 | T3 | T5 | T6 |
 Molecular weight (g/mol) | 454.77 | 450.52 | 402.48 | 558.70 |
 Num. heavy atoms | 33 | 33 | 30 | 40 |
 Num. rotatable bonds | 5 | 4 | 4 | 6 |
 Num. H-bond acceptors | 1 | 6 | 4 | 8 |
 Hydrogen bond donor | 1 | 3 | 0 | 3 |
 MLogP | 7.30 | 2.96 | 3.79 | 1.76 |
 Molar refractivity | 144.50 | 126.11 | 116.15 | 150.94 |
 Lipinski violation | 1 | 0 | 0 | 1 |
(b) admet SAR | ||||
 Absorption (probability) | ||||
  Blood-brain barrier | BBB+ (0.96) | BBB+ (0.60) | BBB+ (0.61) | BBB+ (0.81) |
  Human intestinal absorption | HIA+ (0.99) | HIA+ (0.92) | HIA+ (0.92) | HIA+ (0.97) |
  Bioavailability score | 0.55 | 0.55 | 0.55 | 0.55 |
  Caco-2 permeability | Caco2+ (0.79) | Caco2+ (0.59) | Caco2+ (0.59) | Caco2+ (0.61) |
  P-glycoprotein substrate | Substrate (0.73) | Substrate (0.78) | Non-inhibitor (0.58) | Substrate (0.79) |
  P-glycoprotein inhibitor | Non-inhibitor (0.65) | Non-inhibitor (0.74) | Non-inhibitor (0.74) | Non-inhibitor (0.61) |
  Renal organic cation transporter | Inhibitor (0.75) | Inhibitor (0.90) | Non-inhibitor (0.90) | Non-inhibitor (0.87) |
 Distribution (probability) | ||||
  Subcellular localization | Lysosome (0.55) | Mitochondria (0.86) | Mitochondria (0.86) | Mitochondria (0.77) |
 Metabolism | ||||
  CYP450 substrate | Substrate (0.77) Non-inhibitor (0.78) | Substrate Non-inhibitor (0.83) | Non-substrate (0.65) inhibitor (0.80) | Inhibitor (0.79) Non-substrate (0.83) |
 Toxicity | ||||
  AMES toxicity | Non-AMES toxic (0.71) | AMES toxic (0.87) | Non-AMES toxic (0.87) | Non-AMES toxic (0.84) |
  Carcinogens | Non-carcinogens (0.92) | Non-carcinogens (0.90) | Non-carcinogens (0.90) | Non-carcinogens (0.92) |
  Acute oral toxicity | III (0.77) | III (0.59) | III (0.57) | I (0.78) |
  Rat acute toxicity LD50, mol/kg | 3.2804 | 2.5370 | 2.5370 | 3.8742 |
  Aqueous solubility (LogS) | − 4.76258 | − 4.5550 | − 4.7201 | − 4.5035 |
 Pharmacokinetics | ||||
  Lower GI absorption | Low | High | High | Low |
  Log Kp (skin permeation) cm/s | − 1.48 | − 5.58 | − 5.33 | − 7.83 |